Abstract
HERMES is a prospective study, including all treatment-naive patients attending scheduled visits at hospitals in the CISAI group in 2007. The present cross-sectional analysis aims to assess the baseline prevalence and characteristics of Metabolic Syndrome (MS) in a population of HIV-positive treatment-naive patients. MS was diagnosed using the National Cholesterol Education Program (NCEP) definitions. A total of 292 subjects were enrolled, median age was 37 years, 75% of them were males. The prevalence of MS was 12.3%. The most frequent trio of abnormalities that led to the diagnosis of MS was high blood pressure, triglycerides and HDL. Univariate analysis showed that MS was associated with the following variables: age, education, physical activity, advanced HIV disease (CDC stage C or HIV-RNA > 100,000 copies + CD4 < 100 cells/mm3). Higher educational levels remained protectively associated with MS in multivariate analysis. A higher risk of MS was also associated with advanced HIV disease. Actually, treatment-naïve HIV-positive patients in an advanced stage of the disease have a higher prevalence of abnormal levels of triglycerides, HDL cholesterol and blood glucose than those at a less advanced stage. These findings of the HERMES study suggest, therefore, that HIV infection per se is associated to MS.
Keywords: HIV, naive, advanced HIV disease, metabolic syndrome, cardiovascular risk
Current HIV Research
Title: Is Metabolic Syndrome Associated to HIV Infection Per Se? Results from the HERMES Study
Volume: 8 Issue: 2
Author(s): Paolo Bonfanti, Giuseppe L.V. De Socio, Patrizia Marconi, Marzia Franzetti, Canio Martinelli, Francesca Vichi, Giovanni Penco, Giordano Madeddu, Giancarlo Orofino, Laura Valsecchi, Paola Vitiello, Barbara Menzaghi, Carlo Magni and Elena Ricci
Affiliation:
Keywords: HIV, naive, advanced HIV disease, metabolic syndrome, cardiovascular risk
Abstract: HERMES is a prospective study, including all treatment-naive patients attending scheduled visits at hospitals in the CISAI group in 2007. The present cross-sectional analysis aims to assess the baseline prevalence and characteristics of Metabolic Syndrome (MS) in a population of HIV-positive treatment-naive patients. MS was diagnosed using the National Cholesterol Education Program (NCEP) definitions. A total of 292 subjects were enrolled, median age was 37 years, 75% of them were males. The prevalence of MS was 12.3%. The most frequent trio of abnormalities that led to the diagnosis of MS was high blood pressure, triglycerides and HDL. Univariate analysis showed that MS was associated with the following variables: age, education, physical activity, advanced HIV disease (CDC stage C or HIV-RNA > 100,000 copies + CD4 < 100 cells/mm3). Higher educational levels remained protectively associated with MS in multivariate analysis. A higher risk of MS was also associated with advanced HIV disease. Actually, treatment-naïve HIV-positive patients in an advanced stage of the disease have a higher prevalence of abnormal levels of triglycerides, HDL cholesterol and blood glucose than those at a less advanced stage. These findings of the HERMES study suggest, therefore, that HIV infection per se is associated to MS.
Export Options
About this article
Cite this article as:
Bonfanti Paolo, De Socio L.V. Giuseppe, Marconi Patrizia, Franzetti Marzia, Martinelli Canio, Vichi Francesca, Penco Giovanni, Madeddu Giordano, Orofino Giancarlo, Valsecchi Laura, Vitiello Paola, Menzaghi Barbara, Magni Carlo and Ricci Elena, Is Metabolic Syndrome Associated to HIV Infection Per Se? Results from the HERMES Study, Current HIV Research 2010; 8 (2) . https://dx.doi.org/10.2174/157016210790442731
DOI https://dx.doi.org/10.2174/157016210790442731 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
T Cell Replicative Senescence in Human Aging
Current Pharmaceutical Design The “Sympathetic” Kidney: Multiples Effects of Renal Sympathetic Nerve Ablation
Current Hypertension Reviews Targeting miRNAs for Drug Discovery: A New Paradigm
Current Molecular Medicine Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets Harnessing the Potential of Long Non-coding RNAs to Manage Metabolic Diseases
Current Pharmaceutical Design The Molecular Basis of the Interplay between Endothelin-1 and Nitric Oxide and its Relevance for Atherosclerosis and Arterial and Pulmonary Hypertension
Vascular Disease Prevention (Discontinued) Analgesic Considerations for Liver Transplantation Patients
Current Clinical Pharmacology Plant Sterols and Stanols in the Treatment of Dyslipidemia: New Insights into Targets and Mechanisms Related to Cardiovascular Risk
Current Pharmaceutical Design Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?
Current Vascular Pharmacology Multiple Lipid-lowering Treatment in Pediatric Patients with Hyperlipidemia
Medicinal Chemistry Angiogenesis Inhibitors: Current & Future Directions
Current Pharmaceutical Design The IL23/Th17 Pathway as a Therapeutic Target in Chronic Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) The Role of Small, Dense Low-Density-Lipoproteins in Non-Coronary Forms of Atherosclerosis
Vascular Disease Prevention (Discontinued) Pharmacotherapy of Sickle Cell Disease in Children
Current Pharmaceutical Design Nuclear Membranes GPCRs: Implication in Cardiovascular Health and Diseases
Current Vascular Pharmacology Metabolic Syndrome During Menopause
Current Vascular Pharmacology Gender Differences in the Treatment of Ischemic Heart Disease
Current Pharmaceutical Design Recent advances in the management of autoimmune myocarditis: insights from animal studies.
Current Pharmaceutical Design Signs and Related Mechanisms of Ethanol Hepatotoxicity
Current Drug Abuse Reviews Experimental Strategies in Autoimmunity: Antagonists of Cytokines and their Receptors, Nanocarriers, Inhibitors of Immunoproteasome, Leukocyte Migration and Protein Kinases
Current Pharmaceutical Design